Spero Therapeutics, Inc. Additional Paid in Capital, Common Stock
Spero Therapeutics, Inc. (SPRO) had Additional Paid in Capital, Common Stock of $511.97 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-12
- 2026-06-30: Additional Paid in Capital, Common Stock $511.97M.
- 2026-03-31: Additional Paid in Capital, Common Stock $511.14M.
- 2025-12-31: Additional Paid in Capital, Common Stock $510.03M.
- 2025-09-30: Additional Paid in Capital, Common Stock $509.02M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $511.97M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $511.14M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $510.03M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $509.02M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $507.98M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $507.26M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $505.71M 10-K · filed 2026-03-26 |
| 2024-09-30 | $504.20M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $502.05M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $499.94M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $497.91M 10-K · filed 2025-03-27 |
| 2023-09-30 | $495.92M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $493.79M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $491.93M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $489.76M 10-K · filed 2024-03-13 |
| 2022-09-30 | $473.09M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $464.86M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $462.74M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $455.72M 10-K · filed 2023-03-30 |
| 2021-09-30 | $450.08M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $405.92M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $415.95M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $409.72M 10-K · filed 2022-03-31 |
| 2020-09-30 | $391.88M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $313.86M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $305.11M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $273.97M 10-K · filed 2021-03-11 |
| 2018-12-31 | $254.01M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |